We have established proprietary cell technology platforms that scale up the production of highly qualified, cost effective and universal off-the-shelf cellular medicines, and that will enable broader patient access to our therapies.

H&B JISHI is a company specialized in stem cells and regenerative medicine and established by world renown medical experts in stem cells, hematology and clinical researches. The company has applied its proprietary cell technology platforms to build what it believes is the most advanced cellular medicines and related products portfolio in the industry. These proprietary cell bioengineering platforms allow us to develop product candidates that have the potential to significantly improve the treatment of a number of complex and life-threatening diseases.

H&B JISHI has a strong and extensive global intellectual property (IP) portfolio with protection extending in all major markets. This IP position is expected to provide the company with substantial commercial advantages as it develops its product candidates for major markets including China, Europe, the United States, Japan, Russia and Korea. (Patent figures)

The patents that we have obtained, and continue to apply for, cover perinatal MSC technologies and product candidates. These patents also cover the extracellular vesicles (EVs) derived from perinatal MSCs, and the use of EVs for treatment of many diseases and anti-aging activity. Among the indication-specific issued or pending patents covering product candidates derived from our perinatal MSCs are those which provide commercial support for our product candidates: the acute-on-chronic liver failure, diabetic foot ulcer, steriod-refractory acute graft versus host disease, spinal cord injury, stroke, critical limb ischemia and refractory thrombocytopenia.
We also have issued and pending patents covering our other pipeline indications, including type 2 diabetes and its complications, inflammatory bowel disease (e.g.Crohn’s disease), acute respiratory distress syndrome, radiation sky injury, refractory uveitis, and orthopedic disorders.

Our patent portfolio also includes issued and pending coverage of proprietary manufacturing processes that are being used with our current two-dimensional (2D) manufacturing platform as well as the three-dimensional (3D) bioreactor manufacturing processes currently under development. These cells and their EVs patents cover the isolation, purification, banking, expansion, scale up manufacturing, culture conditions, product cryopreservation, release testing and potency assays.